Moberg begins patient enrolment in US and Europe Phase 3 onychomycosis trials
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing...